Performance Assessment of the PMD-200 in Subjects at Neurointensive Care Unit

NATerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

March 8, 2018

Primary Completion Date

November 30, 2019

Study Completion Date

November 30, 2019

Conditions
Anesthesia, General
Interventions
DEVICE

PMD-200

"the patients will be monitored by PMD-200. The technology consists of measurements of a number of nociception-related physiological parameters that corresponds with the autonomic nervous system's response to noxious stimuli, and using the company's proprietary algorithms, 'translating' these measurements into an index that represents the nociceptive response, the NoL™ (Nociception Level) Index. The NoL index is a relative index from 0 to 100, while 0 is no pain/nociception and 100 is extreme pain/nociception."

DEVICE

EEG monitor

An EEG device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.

Trial Locations (1)

Unknown

Galil Medical Center, Nahariya

Sponsors
All Listed Sponsors
lead

Medasense Biometrics Ltd

OTHER

NCT03452163 - Performance Assessment of the PMD-200 in Subjects at Neurointensive Care Unit | Biotech Hunter | Biotech Hunter